Formycon Submits Eylea Biosimilar For European Approval Following Strong Q3
Revenue Increased 113% During First Nine Months Of 2023
Formycon has submitted its aflibercept candidate for European Medicines Agency consideration, following an incredibly strong Q3 which has put the company on track for a promising future.
